153 related articles for article (PubMed ID: 7074181)
1. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
van Kammen DP; Docherty JP; Bunney WE
Biol Psychiatry; 1982 Feb; 17(2):233-42. PubMed ID: 7074181
[TBL] [Abstract][Full Text] [Related]
2. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
van Kammen DP; Docherty JP; Marder SR; Schulz SC; Dalton L; Bunney WE
Arch Gen Psychiatry; 1982 Mar; 39(3):261-6. PubMed ID: 7065839
[TBL] [Abstract][Full Text] [Related]
4. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
Hunt JI; Singh H; Simpson GM
J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
[TBL] [Abstract][Full Text] [Related]
6. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.
Brauer LH; de Wit H
Biol Psychiatry; 1996 Jan; 39(1):26-32. PubMed ID: 8719123
[TBL] [Abstract][Full Text] [Related]
7. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
[TBL] [Abstract][Full Text] [Related]
8. [Dose-effect relations. Doubleblind study on two different doses of pimozide (author's transl)].
Fleischhauer J
Arzneimittelforschung; 1978; 28(9):1491-2. PubMed ID: 582541
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of D-amphetamine on red and blue light-induced photic activation: A novel BOLD fMRI assay of human dopamine function.
Cowan RL; Wood J; Dietrich MS; de B Frederick B; Lukas SE; Renshaw PF
Synapse; 2008 Apr; 62(4):268-72. PubMed ID: 18240321
[TBL] [Abstract][Full Text] [Related]
10. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers.
Brauer LH; De Wit H
Pharmacol Biochem Behav; 1997 Feb; 56(2):265-72. PubMed ID: 9050084
[TBL] [Abstract][Full Text] [Related]
11. Pimozide blocks establishment but not expression of amphetamine-produced environment-specific conditioning.
Beninger RJ; Hahn BL
Science; 1983 Jun; 220(4603):1304-6. PubMed ID: 6857251
[TBL] [Abstract][Full Text] [Related]
12. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
[TBL] [Abstract][Full Text] [Related]
13. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
Friedman J; Ault K; Powchik P
Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
[No Abstract] [Full Text] [Related]
14. Dextro-amphetamine diminishes negative symptoms in schizophrenia.
van Kammen DP; Boronow JJ
Int Clin Psychopharmacol; 1988 Apr; 3(2):111-21. PubMed ID: 3294284
[TBL] [Abstract][Full Text] [Related]
15. Serum prolactin and antipsychotic responses to pimozide in schizophrenia.
Siris SG; van Kammen DP; De Fraites EG
Psychopharmacol Bull; 1978 Jan; 14(1):11-4. PubMed ID: 625528
[No Abstract] [Full Text] [Related]
16. Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.
Rosenblatt JE; Lake CR; van Kammen DP; Ziegler MG; Bunney WE
Psychiatry Res; 1979 Jul; 1(1):45-52. PubMed ID: 298337
[TBL] [Abstract][Full Text] [Related]
17. The effect of pimozide on CSF norepinephrine in schizophrenia.
Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
[TBL] [Abstract][Full Text] [Related]
18. Amphetamine behavioral toxicity: rotational behavior after chronic intrastriatal infusion.
Dougherty GG; Ellinwood EH
Biol Psychiatry; 1981 May; 16(5):479-88. PubMed ID: 7196774
[TBL] [Abstract][Full Text] [Related]
19. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
[TBL] [Abstract][Full Text] [Related]
20. Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.
van Kammen DP; Docherty JP; Marder SR; Rosenblatt JE; Bunney WE
Psychopharmacology (Berl); 1985; 87(1):111-5. PubMed ID: 3933028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
